AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00985452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glow cap system - deactivated
Description: The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
Study NCT02997189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTO-104
Description: 12 mg dexamethasone administered intratympanically
Study NCT02090582 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Structured Palliative Care
Description: Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
Study NCT02090582 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
Study NCT00450866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epothilone B
Description: Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
Study NCT04704765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal breathing training
Description: The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
Study NCT03988114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT03988114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonsteroidal Aromatase Inhibitor (NSAI)
Description: Letrozole administered orally or anastrozole administered orally (physician choice)
Study NCT01962259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study NCT02728778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxin A
Description: Application of botulinum toxin A into the forehead
Study NCT02728778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acupuncture
Description: Application of acupuncture into the forehead
Study NCT03639051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Lung Denervation (TLD)
Description: Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
Study NCT03639051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Medical Care
Description: Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
Study NCT03639051 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Optimal Medical Care
Description: Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
Study NCT01200134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FMISO PET-scanning
Description: Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
Study NCT04545203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage
Description: Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
Study NCT01017575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, Oral, 10 mg, daily, 24-48 weeks
Study NCT01017575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, Oral, 60 mg, daily, 24-48 weeks
Study NCT03649581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: compare the two groups of schizophrenic patients
Description: Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).
Study NCT03649581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compare the two groups of schizophrenic patients
Description: Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).
Study NCT03649581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: compare the two groups of schizophrenic patients versus volunteers
Description: compare the results of the schizophrenic patient group with healthy volunteers
Study NCT03649581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compare the two groups of schizophrenic patients versus volunteers
Description: compare the results of the schizophrenic patient group with healthy volunteers
Study NCT01017575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, daily, 48 weeks
Study NCT01017575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
Study NCT01017575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
Study NCT01017575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
Study NCT02011958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: 40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)
Study NCT01017575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
Study NCT03858465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: intravenous 25 mg of ephedrine
Study NCT03858465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: intravenous 0,3 mg of phenylephrine
Study NCT03616171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP-Extend intervention
Description: 1. One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~2. Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later
Study NCT03616171 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
Study NCT00576212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supportive call
Description: Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
Study NCT03500679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.
Study NCT03500679 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo as an IM injection on Days 1 and 181.
Study NCT02011958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Orally taken every day during 28 days~* 1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)
Study NCT03732703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
Study NCT03732703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
Study NCT03732703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
Study NCT03732703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
Study NCT03732703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax, dexamethasone, ixazomib, pomalidomide
Description: Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Study NCT04098614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Coach Intervention
Description: Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
Study NCT02176967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT02399618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
Study NCT04923165 — intervention group
Intervention type: DEVICE
Intervention: robotic assisted intervention
Description: Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
Study NCT04923165 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical analyses
Description: ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;
Study NCT04923165 — intervention group
Intervention type: DEVICE
Intervention: BIA, hand grip
Description: bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip
Study NCT04923165 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: nutritional assessment, MNA
Description: nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
Study NCT03165669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscospring PostuRite - medium model
Description: Cervical pillow use, 30-minutes instruction session supported by a brochure
Study NCT03165669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
Study NCT04050943 — intervention group
Intervention type: OTHER
Intervention: observational cohort
Description: Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
Study NCT03218150 — intervention group
Intervention type: PROCEDURE
Intervention: cranioplasty
Description: . The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws.
Study NCT02913924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
Study NCT02913924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03103308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk Training and Transplant
Description: Subjects will receive free activity monitors and have three training sessions per week for the duration of their bone marrow transplant treatment
Study NCT03103308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Monitoring and Transplant
Description: Subjects will receive free activity monitors for the duration of their bone marrow transplant treatment
Study NCT03735979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.
Study NCT03735979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (\~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.
Study NCT03735979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV placebo solution
Study NCT02593773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon γ-1b
Description: The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
Study NCT02396459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triac
Description: Triac, individually titrated dose
Study NCT02882373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Given PO
Study NCT02882373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02176967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT02176967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT03732703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Study NCT03732703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Study NCT03732703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor, dexamethasone, ixazomib, pomalidomide
Description: Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Study NCT02626403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
Study NCT02626403 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
Study NCT02176967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02176967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo clinical observation
Study NCT02176967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02176967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02176967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02176967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02441686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02441686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02441686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02441686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Mobilization
Study NCT02441686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Study NCT03965429 — intervention group
Intervention type: OTHER
Intervention: Blood samples (additional tubes from care) longitudinal
Description: Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).
Study NCT03965429 — intervention group
Intervention type: OTHER
Intervention: Blood samples (additional tubes from care) at inclusion
Description: In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.~In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification.
Study NCT02176967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06695286 — intervention group
Intervention type: OTHER
Intervention: Multimodal rehabilitation training at high intensity
Description: In High Intensive Training patients received 1800 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week.~Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise.~No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL.